NOUS-209 shows potential to intercept cancer in its early stages
News
WHO adds first maternal RSV vaccine to prequalification list
Pfizer’s Abrysvo is designed to prevent RSV-associated disease in infants
UK expands mandatory infectious disease reporting requirements
The update is aimed at strengthening local and national surveillance
Orca Bio’s T-cell therapy shows promise in haematological malignancies
The company is preparing to submit the results to the FDA this year
UKHSA announces new effort to tackle hepatitis C
The agency has launched a whole genome sequencing service to monitor the virus
Anocca announces authorisation pancreatic cancer trial
VIDAR-1 trial marks company’s clinical-stage debut
Careology and Entia join forces to transform cancer care
Collaboration brings remote care to cancer patients
Rxulti approved in the European Union for adolescent schizophrenia
EC extends brexpiprazole indication to include adolescents
Grifols clinical trial shows positive results for post-polio patients
Immunoglobulin therapy improves mobility in phase 2/3 study
Minoryx doses first patient with leriglitazone in Rett syndrome study
Phase 2a TREE study assesses safety and efficacy of leriglitazone
Orphelia Pharma explores other pathways for paediatric cancer treatment
Company seeks new direction after negative CHMP opinion on KIZFIZO
Dementia drug neflamapimod shows positive phase 2b trial results
CervoMed’s therapy demonstrates significant improvement in patients
New weight-loss pill shows promising results
Oxford Medical Products targets overweight individuals
Agomab announces positive phase 2a interim results for AGMB-129
FSCD therapy meets all endpoints in interim analysis
Pfizer’s Talzenna therapy accepted for use within NHS Scotland
Scottish Medicines Consortium approves new option for mCRPC patients
